Revelation Biosciences (NASDAQ:REVB) Announces Quarterly Earnings Results

Revelation Biosciences (NASDAQ:REVB) posted its quarterly earnings data on Thursday. The company reported ($5.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.16) by $0.24, FiscalAI reports.

Revelation Biosciences Trading Up 9.3%

REVB traded up $0.33 on Friday, hitting $3.89. 14,458 shares of the stock traded hands, compared to its average volume of 23,642. The business has a fifty day moving average price of $5.51 and a two-hundred day moving average price of $7.90. Revelation Biosciences has a 52 week low of $3.08 and a 52 week high of $40.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.